Combination targeted pills for advanced lung cancer with egfr mutation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of two targeted therapy pills (andamertinib and anlotinib) for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has progressed after taking a previous targeted therapy. The goal is to see if this new combination can stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to nearby tissues or other parts of the body and cannot be removed with surgery.
- Your cancer must have a specific gene change called an EGFR mutation (either exon 19 deletion or L858R).
- Your cancer must have grown or spread after taking only one line of a specific type of EGFR-targeting pill (like osimertinib/Tagrisso).
- You need to have at least one tumor that can be measured and has not been previously treated with radiation (unless it clearly grew after radiation).
- Your overall health should be reasonably good (able to take care of yourself, up and about more than half the day).
- Your blood counts and liver/kidney function must be within certain limits.
- If you have brain metastases, they must be stable or not causing symptoms.
- You must agree to use effective birth control during the study and for 3 months after the last dose (if you or your partner can have children).
- You must not have other active cancers, serious heart problems, or a history of lung inflammation (interstitial lung disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
This trial tests a new combination of two drugs (bempemab and anlotinib) as a first treatment for older adults with advanced lung cancer. The goal is to see if this drug pair can shrink tumors and slow the cancer, possibly without the need for chemo or radiation.
This study tests a combination of two oral targeted drugs—aumolertinib (which targets EGFR) and anlotinib (which blocks blood vessel growth to the tumor)—as a first treatment for advanced lung cancer that has both EGFR and TP53 mutations. It aims to see if the combination works better and is safe compared to standard care.
This study tests whether combining an EGFR-targeted pill with chemotherapy before surgery can shrink or control early-stage non-small cell lung cancer that has an EGFR mutation. It aims to improve outcomes for patients whose tumors can be removed surgically.
This study tests two combinations of drugs to see which works better for people with a specific type of lung cancer that has a change in the EGFR gene. The treatments may help shrink tumors or slow their growth.
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
Hear when a new Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.